ENTRY       D11150                      Drug
NAME        Cenobamate (USAN/INN);
            Xcopri (TN)
PRODUCT     XCOPRI (SK Life Science)
FORMULA     C10H10ClN5O2
EXACT_MASS  267.0523
MOL_WEIGHT  267.6717
CLASS       Metabolizing enzyme substrate
             DG01638  CYP2A6 substrate
             DG02919  CYP2B6 substrate
             DG01639  CYP2C19 substrate
             DG02855  CYP2E1 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
             DG02925  CYP3A5 substrate
             DG02924  UGT substrate
              DG03189  UGT2B4 substrate
              DG03190  UGT2B7 substrate
REMARK      ATC code: N03AX25
            Product: D11150<US>
EFFICACY    Analgesic, Antiepileptic
COMMENT     Treatment of partial-onset seizures
TARGET      GABR [HSA:2554 2555 2556 2557 2558 2559 2560 2561 2562 2563 2564 2565 2566 2567 2568 55879] [KO:K05175 K05181 K05184 K05185 K05186 K05189 K05192]
            SCN1A [HSA:6323] [KO:K04833]
            SCN2A [HSA:6326] [KO:K04834]
            SCN3A [HSA:6328] [KO:K04836]
            SCN4A [HSA:6329] [KO:K04837]
            SCN5A [HSA:6331] [KO:K04838]
            SCN8A [HSA:6334] [KO:K04840]
            SCN9A [HSA:6335] [KO:K04841]
            SCN10A [HSA:6336] [KO:K04842]
            SCN11A [HSA:11280] [KO:K04843]
  PATHWAY   hsa04080(2554+2555+2556+2557+2558+2559+2560+2561+2562+2563+2564+2565+2566+2567+2568+55879)  Neuroactive ligand-receptor interaction
            hsa04727(2554+2555+2556+2557+2558+2559+2560+2561+2562+2563+2564+2565+2566+2567+2568+55879)  GABAergic synapse
METABOLISM  Enzyme: UGT2B7 [HSA:7364], CYP2E1 [HSA:1571], CYP2A6 [HSA:1548], CYP2B6 [HSA:1555]; UGT2B4 [HSA:7363], CYP2C19 [HSA:1557], CYP3A4 [HSA:1576], CYP3A5 [HSA:1577]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             N NERVOUS SYSTEM
              N03 ANTIEPILEPTICS
               N03A ANTIEPILEPTICS
                N03AX Other antiepileptics
                 N03AX25 Cenobamate
                  D11150  Cenobamate (USAN/INN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Anticonvulsants
              Anticonvulsants, Other
               Cenobamate
                D11150  Cenobamate (USAN/INN)
            Drug groups [BR:br08330]
             Metabolizing enzyme substrate
              DG01638  CYP2A6 substrate
               D11150  Cenobamate
              DG02919  CYP2B6 substrate
               D11150  Cenobamate
              DG01639  CYP2C19 substrate
               D11150  Cenobamate
              DG02855  CYP2E1 substrate
               D11150  Cenobamate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D11150  Cenobamate
              DG02925  CYP3A5 substrate
               D11150  Cenobamate
              DG02924  UGT substrate
               DG03189  UGT2B4 substrate
                D11150  Cenobamate
               DG03190  UGT2B7 substrate
                D11150  Cenobamate
            Target-based classification of drugs [BR:br08310]
             Ion channels
              Ligand-gated ion channels
               GABA (ionotropic)
                GABR
                 D11150  Cenobamate (USAN/INN) &lt;US&gt;
              Voltage-gated ion channels
               Sodium channels
                SCN1A
                 D11150  Cenobamate (USAN/INN) &lt;US&gt;
                SCN2A
                 D11150  Cenobamate (USAN/INN) &lt;US&gt;
                SCN3A
                 D11150  Cenobamate (USAN/INN) &lt;US&gt;
                SCN4A
                 D11150  Cenobamate (USAN/INN) &lt;US&gt;
                SCN5A
                 D11150  Cenobamate (USAN/INN) &lt;US&gt;
                SCN8A
                 D11150  Cenobamate (USAN/INN) &lt;US&gt;
                SCN9A
                 D11150  Cenobamate (USAN/INN) &lt;US&gt;
                SCN10A
                 D11150  Cenobamate (USAN/INN) &lt;US&gt;
                SCN11A
                 D11150  Cenobamate (USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11150
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11150
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11150
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D11150
DBLINKS     CAS: 913088-80-9
            PubChem: 376219074
ATOM        18
            1   C8x C    10.6400  -26.0400
            2   C8x C    10.6400  -27.4400
            3   C8x C    11.8524  -28.1400
            4   C8y C    13.0649  -27.4400
            5   C8y C    13.0649  -26.0400
            6   C8x C    11.8524  -25.3400
            7   X   Cl   14.2960  -28.1510
            8   C1c C    14.2960  -25.3290
            9   O7a O    15.5012  -26.0247
            10  C1b C    14.2957  -23.9401
            11  C7a C    16.6835  -25.3419
            12  N1a N    17.8775  -26.0312
            13  O6a O    16.6835  -23.9402
            14  N4y N    13.0714  -23.2334
            15  N5x N    13.0557  -21.8404
            16  C8x C    11.7275  -21.4260
            17  N5x N    10.9229  -22.5612
            18  N5x N    11.7539  -23.6772
BOND        19
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     4   7 1
            8     5   8 1
            9     8   9 1 #Down
            10    8  10 1
            11    9  11 1
            12   11  12 1
            13   11  13 2
            14   10  14 1
            15   14  15 1
            16   15  16 2
            17   16  17 1
            18   17  18 2
            19   14  18 1
///
